World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
27354
World Ranking
17430
National Ranking
8724

Overview

Ulka N. Vaishampayan is affiliated with the University of Michigan-Ann Arbor in the United States. Their research spans several areas within medicine, with significant focus on oncology, molecular biology, and cancer research. The scholar has contributed extensively to the study and treatment of renal and related cancers, prostate cancer, and cancer immunotherapy, among other fields.

The main fields of study for Vaishampayan include Medicine and Biochemistry, Genetics and Molecular Biology. Subfields prominently covered in their work are Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Surgery.

The topics frequently addressed in their research comprise:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Treatment and Research
  • Cancer Genomics and Diagnostics
  • Renal and related cancers
  • Bladder and Urothelial Cancer Treatments
  • Radiopharmaceutical Chemistry and Applications

Vaishampayan has published in a variety of journals, with frequent appearances in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • The Journal of Urology

Notable recent papers include:

  • "Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer," 2021, Nature
  • "First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer," 2021, Annals of Oncology
  • "A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial," 2021, The Lancet
  • "Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours," 2021, British Journal of Cancer
  • "A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma," 2020, British Journal of Cancer

Frequent co-authors collaborating with Vaishampayan include:

  • Sumanta K. Pal
  • Toni K. Choueiri
  • Ajjai Alva
  • Elisabeth I. Heath
  • Michael Staehler

Best Publications

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Intermittent versus continuous androgen deprivation in prostate cancer.

    Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano

  • Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study

    Emmanuel S. Antonarakis;Josep M. Piulats;Marine Gross-Goupil;Jeffrey Goh;Jeffrey Goh

  • Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

    David C. Smith;Matthew R. Smith;Christopher Sweeney;Aymen A. Elfiky

  • Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Toni K. Choueiri;Ulka Vaishampayan;Jonathan E. Rosenberg;Theodore F. Logan

  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck

  • Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn

  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Andrew J Armstrong;Susan Halabi;Tim Eisen;Samuel Broderick

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer

    Ronald M. Bukowski;Fairooz F. Kabbinavar;Robert A. Figlin;Keith Flaherty

  • The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

    Jenny J. Ko;Wanling Xie;Nils Kroeger;Jae lyun Lee

  • Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

    Michael B Atkins;Elizabeth R Plimack;Igor Puzanov;Mayer N Fishman

  • Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

    Lucia Nogova;Lecia V. Sequist;Jose Manuel Perez Garcia;Fabrice Andre

  • Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder : Prognostic significance and comparative analysis in primary and metastatic tumors

    Rafael E. Jimenez;Maha Hussain;Fernando J. Bianco;Ulka Vaishampayan

  • Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer

    Maha Hussain;Ulka Vaishampayan;Wei Du;Bruce Redman

  • A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

    Elisabeth I. Heath;David W. Hillman;Ulka Vaishampayan;Shijie Sheng

  • Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

    Rana R. McKay;Nils Kroeger;Nils Kroeger;Wanling Xie;Jae Lyun Lee

  • Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

    Sumanta K. Pal;Jonathan E. Rosenberg;Jean H. Hoffman-Censits;Raanan Berger

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Thomas Powles
Thomas Powles Queen Mary University of London
Maha Hussain
Maha Hussain Northwestern University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Sun Young Rha
Sun Young Rha Yonsei University
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Cora N. Sternberg
Cora N. Sternberg Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine or healthcare, exploring related online degrees can expand your opportunities and flexibility. Many students find that not all roles in healthcare require attending traditional, in-person medical school. For example, a healthcare administration accelerated degree can fast-track your path to leadership positions in hospitals or clinics, with programs designed for working professionals and career changers alike.

For nurses aiming to become Family Nurse Practitioners, rn to fnp programs offer online bridge options that streamline the journey from an Associate Degree in Nursing to a Master of Science in Nursing.

Nutrition also plays a vital role in health. A bachelor's in nutrition online prepares graduates for careers in dietetics, wellness coaching, and community health without needing to relocate or pause employment.

If your interests lie in healthcare management, pursuing cahme-accredited online mha programs ensures you receive a quality education recognized by employers, opening doors to senior administrative roles nationwide.

Best Scientists Citing Ulka N. Vaishampayan

Trending Scientists